• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    BioXcel Therapeutics Reveals SERENITY Phase 3 Safety Trial

    GLOBENEWSWIRE

    BioXcel Locks SERENITY Ph 3 Data in Bipolar, Schizophrenia

    GLOBENEWSWIRE

    BioXcel Gets FDA Pre-sNDA Feedback for BXCL501 in Disorder

    GLOBENEWSWIRE

    BioXcel Joins H.C. Wainwright & Co. `HCW@Home` Series

    GLOBENEWSWIRE

    BioXcel Therapeutics Q2 2025 Financial Results & Business Updates

    GLOBENEWSWIRE

    BioXcel Joins Canaccord Genuity 45th Annual Growth Conference

    GLOBENEWSWIRE

    BioXcel Therapeutics Publishes Study on Dexmedetomidine Effects

    GLOBENEWSWIRE

    Biocel Wraps up Serenity Trial for Treating Agitation

    GLOBENEWSWIRE

    BioXcel Submits Pre-Supplemental Drug App for IGALMI Expansion

    GLOBENEWSWIRE

    BioXcel Therapeutics Receives Second Positive DSMB Recommendation

    GLOBENEWSWIRE

    BioXcel Therapeutics Granted Extension for Nasdaq Compliance

    GLOBENEWSWIRE

    BioXcel Gets DSMB Greenlight for Serenity Ph3 Trial

    GLOBENEWSWIRE

    BioXcel Therapeutics Reports Q1 2025 Results and Business Update

    GLOBENEWSWIRE

    BioXcel Therapeutics Reports Q4 2024 Financial Results

    GLOBENEWSWIRE

    BioXcel Therapeutics boosts cash to advance SERENITY trial

    GLOBENEWSWIRE

    BioXcel Hits 33% Enrollment In Serenity Ph3 Agitation Trial

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Closes $14M Offering

    GLOBENEWSWIRE

    BioXcel FDA Closes Site Inspection For Ph3 TRANQUILITY II Trial

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces $14 M Registered Direct Offering

    GLOBENEWSWIRE

    BioXcel Regains Nasdaq Compliance On Minimum Bid Price Rule

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Reverse Stock Split

    GLOBENEWSWIRE

    BioXcel Therapeutics Provides Clinical and Business Update

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces $7M Public Offering Pricing

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Proposed Public Offering

    GLOBENEWSWIRE

    BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

    GLOBENEWSWIRE

    BioXcel Advances BXCL501 Phase 3 Trials for Agitation Treatment

    GLOBENEWSWIRE

    BioXcel Therapeutics to Report Q3 2024 Financial Results on Nov 14

    GLOBENEWSWIRE

    BioXcel Therapeutics to Present at ThinkEquity Conference

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Update On BXCL501 Programs

    GLOBENEWSWIRE

    BioXcel Therapeutics Initiates SERENITY At-Home Trial

    GLOBENEWSWIRE

    BioXcel Therapeutics To Participate In Canaccord Genuity Growth Conference

    GLOBENEWSWIRE

    BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

    GLOBENEWSWIRE

    BioXcel Therapeutics To Report Q2 2024 Results On August 6

    GLOBENEWSWIRE

    BioXcel Announces Preliminary Q2 IGALMI Net Revenues

    GLOBENEWSWIRE

    BioXcel TAnnounces Positive Results from PRN Treatment Study for Agitation

    GLOBENEWSWIRE

    BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    BioXcel Announces ASCP 2024 Oral, Poster Presentations

    GLOBENEWSWIRE

    BioXcel Therapeutics Reports First Quarter 2024 Financial Results

    GLOBENEWSWIRE

    BioXcel to Report First Quarter 2024 Financial Results on May 9, 2024

    GLOBENEWSWIRE

    BioXcel`s BXCL701+KEYTRUDA in PDAC Data at ASCO 2024

    GLOBENEWSWIRE

    BioXcel Plans BXCL501 At-Home Setting Evaluation

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces TRANQUILITY Trial Plan for BXCL501

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces $25 Million Registered Direct Offering

    GLOBENEWSWIRE

    BioXcel Announces Patent Office Grant of Patent for Method of Treating Agitation

    GLOBENEWSWIRE

    BioXcel Reports Financial Results for the Fourth Quarter and Full Year 2023

    GLOBENEWSWIRE

    BioXcel to Report Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Termination of Proposed Public Offering

    GLOBENEWSWIRE

    BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Proposed Public Offering

    GLOBENEWSWIRE

    BioXcel Announces Completion of Patient Enrollment in Phase 2 Trial of BXCL701

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

    GLOBENEWSWIRE

    BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

    GLOBENEWSWIRE

    BioXcel Strengthens Leadership to Advance Late-Stage Programs

    GLOBENEWSWIRE

    BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

    PRESS RELEASE

    BioXcel Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program

    GLOBENEWSWIRE

    BioXcel Reports Positive Overall Survival Results form Phase 2 Trial of BXCL701

    GLOBENEWSWIRE

    BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501

    GLOBENEWSWIRE

    BioXcel to Report Third Quarter 2023 Financial Results on November 14, 2023

    GLOBENEWSWIRE

    BioXcel Therapeutics Receives Permanent J-Code for IGALMI

    GLOBENEWSWIRE

    Despite misconduct at trial site, BioXcel touts audit`s findings

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.